Prognostic impact of pretreatment cell‐free <scp>DNA</scp> concentration in newly diagnosed peripheral T‐cell lymphomas-Reference-Cited by-同舟云学术

Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas

Published:2024-01-04 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Fardella E.¹^ORCID,Zanirato G.²,Magni M.²,Caldarelli N.¹,Chiappella A.²^ORCID,Dodero A.²,Ljevar S.³,Orsucci L.⁴,Re A.⁵,Usai S. V.⁶,Stefoni V.⁷,Castellino C.⁸,Rossi F. G.⁹,Pinto A.¹⁰^ORCID,Carniti C.²^ORCID,Corradini P.¹²^ORCID

Affiliation:

1. University of Milan Milan Italy

2. Division of Hematology and Stem Cell Transplantation Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

3. Unit of Biostatistics for Clinical Research Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy

4. Division of Hematology Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Turin Italy

5. Hematology Division ASST Spedali Civili di Brescia Brescia Italy

6. Hematology Unit Ospedale Oncologico Armando Businco Cagliari Italy

7. Institute of Hematology Seràgnoli University of Bologna Bologna Italy

8. Division of Hematology Azienda Ospedaliera S. Croce e Carle Cuneo Italy

9. Division of Hematology Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico Milan Italy

10. Hematology‐Oncology & Stem Cell Transplantation Unit IRCCS Istituto Nazionale Tumori, Fondazione G. Pascale Napoli Italy

Abstract

SummaryPeripheral T‐cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the prognostic impact of cell‐free DNA (cfDNA) concentration in 75 newly diagnosed patients enrolled in a prospective multicenter study. Pre‐treatment cfDNA was strongly associated with clinical risk factors and was identified as a superior predictor for shorter progression‐free survival in multivariable analysis, outweighing canonical risk parameters. Furthermore, we identified a cfDNA value above which survival worsens. In conclusion, pre‐treatment cfDNA concentration represents an easily usable predictive biomarker that is highly associated with survival of PTCL patients.

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19280

Reference11 articles.

1. How I treat the peripheral T-cell lymphomas

2. Cell-Free DNA: Hope and Potential Application in Cancer

3. Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients

4. Circulating nucleic acids (CNAs) and cancer—A survey